Drug Profile
Lidocaine/tetracaine topical cream - Crescita Therapeutics
Alternative Names: Flexicaine; Pliaglis; S-Caine™ Peel; Tetracaine/lidocaine topical cream - Crescita TherapeuticsLatest Information Update: 10 Nov 2023
Price :
$50
*
At a glance
- Originator ZARS
- Developer Crescita Therapeutics; Galderma; Nuvo Research
- Class Acetanilides; Aminobenzoic acids; Local anaesthetics; Small molecules
- Mechanism of Action Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Marketed Procedural pain
- Phase II Unspecified
- Discontinued Postherpetic neuralgia
Most Recent Events
- 25 Oct 2023 Taro Pharmaceuticals delivers a notice to terminate the license agreement for Pliaglis® in the USA
- 01 Jun 2023 Croma-Pharma intends to launch lidocaine/tetracaine topical cream in other countries including Germany, the United Kingdom, Ireland, Switzerland, Brazil, Romania, Belgium, the Netherlands, Luxembourg and Brazil in 2023
- 13 Dec 2021 Crescita Therapeutics and Egis Pharmaceuticals enters into an exclusive license agreement for lidocaine/tetracaine topical cream in Hungary, Bulgaria, Czech Republic, Slovakia, Poland, Russia, Latvia and Lithuania